AR091977A1 - El uso de antitrombina en la oxigenacion de membranas extracorporeas - Google Patents
El uso de antitrombina en la oxigenacion de membranas extracorporeasInfo
- Publication number
- AR091977A1 AR091977A1 ARP130102756A ARP130102756A AR091977A1 AR 091977 A1 AR091977 A1 AR 091977A1 AR P130102756 A ARP130102756 A AR P130102756A AR P130102756 A ARP130102756 A AR P130102756A AR 091977 A1 AR091977 A1 AR 091977A1
- Authority
- AR
- Argentina
- Prior art keywords
- oxygenation
- extracorpore
- antitrombin
- membranes
- antithrombin
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title 1
- 238000006213 oxygenation reaction Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 239000004019 antithrombin Substances 0.000 abstract 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 229940089003 atryn Drugs 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Métodos para la supresión de la coagulación de la sangre y/o la prevención de la hemorragia en un sujeto que recibe oxigenación por membrana extracorpórea que comprende la administración de antitrombina. En algunas formas de realización, la antitrombina que se utiliza en los métodos descritos en el presente documente es ATryn®. Reivindicación 10: El método de una cualquiera de las reivindicaciones 1 - 8, en donde la antitrombina se administra a una dosis de 295 unidades por kg. Reivindicación 14: El método de una cualquiera de las reivindicaciones 1 - 13, que comprende además la administración de heparina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679345P | 2012-08-03 | 2012-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091977A1 true AR091977A1 (es) | 2015-03-11 |
Family
ID=50028554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102756A AR091977A1 (es) | 2012-08-03 | 2013-08-02 | El uso de antitrombina en la oxigenacion de membranas extracorporeas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9511087B2 (es) |
| EP (1) | EP2879697A4 (es) |
| JP (1) | JP6389172B2 (es) |
| KR (1) | KR20150039201A (es) |
| CN (1) | CN104884080A (es) |
| AR (1) | AR091977A1 (es) |
| AU (1) | AU2013296240B2 (es) |
| BR (1) | BR112015002321A2 (es) |
| CA (1) | CA2879763C (es) |
| IL (1) | IL236776A0 (es) |
| MX (1) | MX2015001508A (es) |
| TW (1) | TW201425332A (es) |
| WO (1) | WO2014022748A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501365A1 (en) | 2010-12-30 | 2013-09-16 | Laboratoire Francais Du Fractionnment Et Des Biotechnologies | Glycols as pathogen inactivating agents |
| WO2014022748A1 (en) | 2012-08-03 | 2014-02-06 | Revo Biologics, Inc. | The use of antithrombin in extracorporeal membrane oxygenation |
| BR112015019341A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| TW201509432A (zh) | 2013-07-05 | 2015-03-16 | Lab Francais Du Fractionnement | 親和層析基質 |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| EP3388140A1 (en) * | 2017-04-10 | 2018-10-17 | Gambro Lundia AB | Extracorporeal blood circuit |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4517294A (en) | 1982-03-03 | 1985-05-14 | Genentech, Inc. | Human antithrombin III |
| US4632981A (en) | 1982-07-30 | 1986-12-30 | Genentech, Inc. | Human antithrombin III |
| EP0264166B1 (en) | 1986-04-09 | 1996-08-21 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
| US6727405B1 (en) | 1986-04-09 | 2004-04-27 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
| US5366894A (en) | 1986-06-30 | 1994-11-22 | Pharmaceutical Proteins Limited | Peptide production |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
| DE4028800A1 (de) | 1990-09-11 | 1992-03-12 | Behringwerke Ag | Gentechnische sialylierung von glykoproteinen |
| DE4326665C2 (de) | 1993-08-09 | 1995-07-13 | Biotest Pharma Gmbh | Verfahren zur Sterilfiltration von Milch |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5843705A (en) * | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US5801063A (en) * | 1995-05-09 | 1998-09-01 | Grandics; Peter | Device and process for the biospecific removal of heparin |
| US6268487B1 (en) | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
| AU6184298A (en) | 1997-02-25 | 1998-09-09 | Genzyme Transgenics Corporation | Transgenically produced non-secreted proteins |
| US20060264357A1 (en) | 1997-04-22 | 2006-11-23 | Zikria Bashir A | Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals |
| US8257724B2 (en) | 1998-09-24 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
| DE10159556A1 (de) | 2001-12-05 | 2003-06-12 | Aventis Behring Gmbh Intellect | Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen |
| SE521676C2 (sv) | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US7191068B2 (en) | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
| WO2005024044A2 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| CA2479968A1 (en) | 2004-09-01 | 2006-03-01 | Keith R. Walley | Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome |
| EP1776108A1 (en) | 2004-06-23 | 2007-04-25 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| AU2006261555A1 (en) | 2005-06-23 | 2006-12-28 | The University Of British Columbia | Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy |
| US20070037192A1 (en) | 2005-07-25 | 2007-02-15 | Gtc Biotherapeutics, Inc. | Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile |
| ES2417147T3 (es) | 2005-10-21 | 2013-08-06 | Revo Biologics, Inc. | Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso |
| US20070292407A1 (en) | 2005-12-12 | 2007-12-20 | The Board Of Trustees Operating Michigan State University | Methods of treatment for meconium aspiration syndrome |
| US7531632B2 (en) | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
| US8173860B2 (en) | 2006-04-21 | 2012-05-08 | Gtc Biotherapeutics, Inc. | Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion |
| WO2009097584A1 (en) | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
| US20110082083A1 (en) | 2009-04-10 | 2011-04-07 | Gtc Biotherapeutics, Inc. | Formulations of liquid stable antithrombin |
| US8551096B2 (en) | 2009-05-13 | 2013-10-08 | Boston Scientific Scimed, Inc. | Directional delivery of energy and bioactives |
| WO2013006766A2 (en) | 2011-07-07 | 2013-01-10 | Gtc Biotherapeutics, Inc. | Formulations that stabilize proteins |
| TW201400499A (zh) | 2012-03-12 | 2014-01-01 | Revo Biolog Inc | 抗凝血酶用於治療妊娠毒血症之用途 |
| WO2014022748A1 (en) | 2012-08-03 | 2014-02-06 | Revo Biologics, Inc. | The use of antithrombin in extracorporeal membrane oxygenation |
-
2013
- 2013-08-02 WO PCT/US2013/053365 patent/WO2014022748A1/en not_active Ceased
- 2013-08-02 EP EP13825397.6A patent/EP2879697A4/en not_active Withdrawn
- 2013-08-02 US US14/239,943 patent/US9511087B2/en not_active Expired - Fee Related
- 2013-08-02 CN CN201380041286.1A patent/CN104884080A/zh active Pending
- 2013-08-02 AU AU2013296240A patent/AU2013296240B2/en not_active Ceased
- 2013-08-02 MX MX2015001508A patent/MX2015001508A/es unknown
- 2013-08-02 KR KR1020157002667A patent/KR20150039201A/ko not_active Ceased
- 2013-08-02 BR BR112015002321A patent/BR112015002321A2/pt not_active IP Right Cessation
- 2013-08-02 JP JP2015525617A patent/JP6389172B2/ja not_active Expired - Fee Related
- 2013-08-02 TW TW102127828A patent/TW201425332A/zh unknown
- 2013-08-02 AR ARP130102756A patent/AR091977A1/es unknown
- 2013-08-02 CA CA2879763A patent/CA2879763C/en active Active
-
2015
- 2015-01-18 IL IL236776A patent/IL236776A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013296240A1 (en) | 2015-02-12 |
| EP2879697A4 (en) | 2016-01-20 |
| IL236776A0 (en) | 2015-03-31 |
| JP2015524823A (ja) | 2015-08-27 |
| KR20150039201A (ko) | 2015-04-09 |
| TW201425332A (zh) | 2014-07-01 |
| CA2879763A1 (en) | 2014-02-06 |
| US9511087B2 (en) | 2016-12-06 |
| US20140194360A1 (en) | 2014-07-10 |
| BR112015002321A2 (pt) | 2019-10-22 |
| AU2013296240B2 (en) | 2018-05-17 |
| CN104884080A (zh) | 2015-09-02 |
| CA2879763C (en) | 2020-12-01 |
| WO2014022748A1 (en) | 2014-02-06 |
| MX2015001508A (es) | 2015-04-08 |
| EP2879697A1 (en) | 2015-06-10 |
| JP6389172B2 (ja) | 2018-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091977A1 (es) | El uso de antitrombina en la oxigenacion de membranas extracorporeas | |
| WO2015084698A3 (en) | Administration and monitoring of nitric oxide in ex vivo fluids | |
| DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| CR20170279A (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
| CO7190239A2 (es) | Dialisato a base de polímero | |
| BR112016010103A8 (pt) | métodos, kits e dispositivos de suprimento de fármaco osmótico. | |
| CL2012003038A1 (es) | Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia. | |
| BR112015012014A2 (pt) | proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb) | |
| PE20150226A1 (es) | Agentes terapeuticos para administracion subcutanea optimizados | |
| CL2015002747A1 (es) | Metodo para la oxigenacion extracorporea de un sujeto; y aparato de incubacion. | |
| BR112016026243A2 (pt) | membrana, molécula de fibra oca, uso de uma membrana, e, copolímero em bloco | |
| DOP2016000102A (es) | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
| CL2013001382A1 (es) | Metodo para aumentar la seguridad y la eficacia de las transfusiones de sangre, que comprende administrar a un paciente una composicion farmaceutica que comprende un copolimero de polioxietileno/polioxipropileno, en donde la composicion se mezcla con la sangre antes de la transfusion, o se administra al paciente antes o despues de la transfusion. | |
| GT200900319A (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| ECSP10010553A (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
| CL2015001943A1 (es) | Derivados de bencilamina | |
| NI201000181A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona. | |
| CL2013000021A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable. | |
| DOP2015000175A (es) | Uso de un péptido natriurético, un péptido diurético o un péptido vasodilatador en la elaboración de un medicamento para tratar una condición cardiovascular | |
| UA112488C2 (uk) | Три(гетеро)арилпіразоли і їх застосування | |
| MX2017014731A (es) | Eliminacion de linfocitos b como marcador diagnostico. | |
| BR112014005221A2 (pt) | uso de materiais de fibra oca modificada para a remoção de exotoxinas produzidas por escherichia coli a partir de liquidos, de preferência a partir de sangue e de plasma, bem como seu uso para o tratamento de doenças concomitantes | |
| AR105503A1 (es) | Concentrado que contiene alprostadil | |
| CO6670569A2 (es) | Agentes anti-inflamatorios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |